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ABSTRACT
Introduction: Population screening for abdominal
aortic aneurysms (AAA) halves the associated mortality
and has led to the establishment of national screening
programmes. Prediction of aneurysm growth and
rupture is challenging and currently relies on serial
diameter measurements with ultrasound. Recently,
a novel MRI-based technique using ultrasmall
superparamagnetic particles of iron oxide (USPIO) has
demonstrated considerable promise as a method of
identifying aneurysm inflammation and expansion.
Methods and analysis: The MA3RS study is a
prospective observational multicentre cohort study
of 350 patients with AAA in three centres across
Scotland. All participants will undergo MRI with USPIO
and aneurysm expansion will be measured over 2 years
with CT in addition to standard clinical ultrasound
surveillance. The relationship between mural USPIO
uptake and subsequent clinical outcomes, including
expansion, rupture and repair, will be evaluated and
used to determine whether the technique augments
standard risk prediction markers. To ensure adequate
sensitivity to answer the primary question, we need to
observe 130 events (composite of rupture or repair)
with an estimated event rate of 41% over 2 years of
follow-up. The MA3RS study is currently recruiting and
expects to report in 2017.
Discussion: This is the first study to evaluate the use of
USPIO-enhanced MRI to provide additional information
to aid risk prediction models in patients with AAA. If
successful, this study will lay the foundation for a large
randomised controlled trial targeted at applying this
technique to determine clinical management.
Trial registration number: Current Controlled Trials:
ISRCTN76413758.
INTRODUCTION
Abdominal aortic aneurysm (AAA) disease is
particularly prevalent in elderly men,
KEY MESSAGES
What is already known about this subject?
▸ Current techniques for estimation of rupture risk
in abdominal aortic aneurysm disease rely solely
on diameter measurements from ultrasound.
However, the absolute diameter of the aneurysm
is not the sole determinant of the risk of rupture.
▸ USPIO-enhanced MRI can be used to detect
focal hotspots of inflammation in asymptomatic
aneurysms, and mural USPIO uptake is asso-
ciated with more rapid expansion of aneurysms.
What does this study add?
▸ The aim of the MA3RS study is to examine the
relationship between mural USPIO uptake and
subsequent clinical outcomes.
How might this impact on clinical practice?
▸ This technique may provide an improved method
of risk stratification of patients with abdominal
aortic aneurysms that extends beyond simple
anatomical measurements of aneurysm diameter.
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affecting 5% of men over the age of 65 years1 and
causing 2–3% of deaths within this group.2 Aneurysm
rupture is associated with a mortality rate in excess of
80%.3 4 Population screening halves the mortality asso-
ciated with AAA and has led to the establishment of
national screening and surveillance programmes.1
However, once an aneurysm has been diagnosed, there is
currently no accurate method of predicting which
patients are at risk of rupture and would beneﬁt from
elective surgical or endovascular intervention.
The aetiology of AAA is multifactorial, with environ-
mental and genetic factors playing a part. Aneurysms
typically occur in patients with atherosclerosis and there
are a number of common risk factors, however, there
are also distinct differences between the two disease pro-
cesses. Atherosclerotic lesions are predominantly located
within the tunica intima, whereas aneurysm disease
affects the media and also the adventitia. Aneurysm
disease is most commonly conﬁned to the infrarenal
aorta, whereas atherosclerosis is generally more wide-
spread throughout the arterial tree. In aneurysm
disease, cigarette smoking and hypertension are more
strongly correlated with incidence and risk of rupture.5
The combined effects of biomechanical factors and bio-
logical processes weaken the aortic wall, and lead to aneur-
ysm formation, expansion and rupture. Histopathologically,
the aneurysmal aortic wall is characterised by focal
medial neovascularisation, inﬁltration of inﬂammatory cells
(principally macrophages) and fragmentation of elastin
and collagen ﬁbres within the extracellular matrix. Regions
of intense biological activity represent sites of potential
rupture, and can be considered as putative targets for novel
imaging techniques to predict aneurysm expansion and
assess the risk of rupture. In addition, tissue and wall stresses
vary spatially within the aneurysm, and tensile strength
varies in different parts of the aneurysm sac.6 7 It is likely
that expansion and rupture occur where regions of high
biomechanical stress coincide with these biological ‘hot-
spots’ in the aneurysm wall that have become weakened.
Indeed, there is strong evidence that aneurysm rupture is
seen in those patients with more rapid aneurysm expansion
rates.8 9
MRI
MRI is increasingly being used as an investigative tool
for cardiovascular disease, enabling distinction between
the different atherosclerotic plaque components, such
as the lipid-rich necrotic core, ﬁbrous cap and areas of
calciﬁcation.10 Standard gadolinium-based MRI is able
to identify areas of thrombus formation and ﬁbrosis in
AAA.11 However, recent innovations in cellular and
molecular imaging methods have enabled the detection
of key biological processes and vessel characteristics that
may correlate with aneurysm disease progression.12–14
Superparamagnetic particles of iron oxide (SPIO) are
part of a novel class of MRI contrast agents that provide
additional biological and functional information
through the detection of cellular inﬂammation within
tissues. Current preparations of ultrasmall SPIO
(USPIO) are biodegradable and safe for clinical admin-
istration.15–17 USPIO are phagocytosed by macrophages
within vascular and lymphatic tissues,18–21 and can be
used to detect tissue inﬂammation. USPIO accumulate
in ruptured and vulnerable carotid plaques, and
USPIO-enhanced MRI can detect a reduction in plaque
inﬂammation following treatment with high-dose ator-
vastatin.22 USPIO uptake has also been demonstrated in
other regions of the vasculature, including the aorta, in
preclinical models and also in small clinical studies.23 24
We have recently conducted a series of MRI studies in
patients with AAA and shown that uptake of USPIO in
the aortic wall correlates with macrophage activity, and
identiﬁes cellular inﬂammation.25 Using a 3 T MR
scanner, patients with asymptomatic AAA (n=29; aneur-
ysm diameter 4.0–6.6 cm) attending our surveillance
programme were imaged before and 24–36 h after intra-
venous administration of USPIO. Histological examin-
ation of aneurysm tissue conﬁrmed co-localisation and
uptake of USPIO in areas of macrophage inﬁltration.
Patients exhibiting USPIO uptake and inﬂammation
within the wall of their aneurysm had a threefold higher
aneurysm expansion rate (n=11, 0.66 cm/year; p=0.020)
than patients with no (n=6, 0.22 cm/y) or non-speciﬁc
(n=8, 0.24 cm/y) USPIO uptake, despite similar baseline
anteroposterior diameters.25 Indeed, one patient with a
hotspot of USPIO uptake and biological activity within
the wall of an aneurysm, died suddenly 2 months after
scanning, from presumed aneurysm rupture.
We have shown that USPIO-enhanced MRI holds
major promise as a new method of risk-stratiﬁcation of
patients with AAA and extends beyond simple anatom-
ical measurements of aneurysm diameter. The aim of
this present study is to validate this technique within a
larger multicentre cohort study and to examine the rela-
tionship between baseline USPIO uptake and subse-
quent aneurysm expansion, requirement for elective
repair and incidence of rupture.
METHODS AND ANALYSIS
Study design
The study is a prospective observational multicentre
cohort study of patients with AAA disease under routine
clinical surveillance, and will assess the role of MRI with
USPIO to predict clinical disease progression.
Study objectives
Our previous proof-of-concept study25 demonstrated
that MRI with USPIO had the potential to predict clin-
ical disease progression in patients with asymptomatic
AAA. The aim of this study is to validate these ﬁndings,
focusing on the relationship between baseline USPIO
uptake and the subsequent clinical outcome and aneur-
ysm expansion rates.
The primary objective of the study is to determine
whether mural uptake of USPIO in AAA provides
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incremental risk prediction in addition to standard risk
markers such as aneurysm diameter, smoking and blood
pressure.
Secondary objectives of the study are to ascertain
whether mural uptake of USPIO in AAA: (1) correlates
with the rate of aneurysm expansion; (2) occurs more
commonly in patients who progress to surgery or whose
aneurysm subsequently ruptures; (3) co-localises with, or
relates to, areas of biomechanical stress and (4) occurs
in a reproducible manner.
We will also investigate other inter-related mechanisms
associated with aneurysm growth. We will speciﬁcally
explore the added value of biomechanical stress model-
ling as we suspect co-localisation of USPIO uptake and
areas of high mechanical stress could act synergistically,
and cause more marked aneurysm growth. We will also
examine correlates with other blood biomarkers includ-
ing regulators of extracellular matrix turnover (such as
matrix metalloproteinases and tissue inhibitors of metal-
loproteinases) and vascular inﬂammation (such as C
reactive protein and interleukin 6).
Reproducibility of the technique will be assessed in a
subgroup (n=20) of study participants (from the
Edinburgh study centre) who will undergo repeat MRI
and USPIO administration at <1 month and 1 year.
Short-term (<1 month) reproducibility is likely to reﬂect
the variability in USPIO uptake whereas long-term
(1 year) reproducibility is likely to represent the vari-
ation in biology of the aortic aneurysm with time.
This will lay the foundation for a large multicentre
randomised controlled trial targeted at applying this
technique to determine clinical management and surgi-
cal intervention. This will be particularly important
given the fact that screening programmes for the detec-
tion of AAA are being rolled out in many countries and
this is likely to increase substantially the number of
patients being entered into surveillance programmes.
Study end points
The primary endpoint of the study will be the composite
rate of aneurysm rupture or repair. The following sec-
ondary endpoints will be evaluated: (1) the rate of
aneurysm rupture; (2) the rate of surgical or endovascu-
lar repair of the aneurysm; (3) the aneurysm growth
rate and (4) all-cause and aneurysm-related mortality.
We will conduct exploratory analyses examining the
interactions between mural USPIO uptake, biomechan-
ical stress, clinical risk factors, and serum biomarkers of
extracellular matrix turnover and inﬂammation.
Study population
Participants will be identiﬁed from clinical surveillance
programmes and databases at three centres: Royal
Inﬁrmary of Edinburgh, Western Inﬁrmary in Glasgow
and Forth Valley Royal Hospital (FVRH). We will recruit
350 participants over a 24-month period with recruit-
ment having begun on 6 November 2012. Recruitment
rate and summary statistics can be viewed at online sup-
plementary appendix 2.
Inclusion criteria will be: (1) AAA measuring ≥4.0 cm
in anteroposterior diameter on ultrasound scanning and
(2) age ≥40 years. Patients under the age of 40 years will
be excluded since they may have a connective tissue dis-
order accounting for their disease.
Exclusion criteria will be: (1) patients expected to
undergo imminent elective or emergency surgical or
endovascular repair; (2) contraindication to MRI scanning
identiﬁed from MRI safety questionnaire; (3) patients
refusing or unable to give informed consent; (4) women
with childbearing potential or who are breast feeding will
not be enrolled into the study (women who are currently
pregnant or have experienced menarche but are preme-
nopausal and have not been sterilised will be excluded);
(5) intercurrent illness including patients with a systemic
inﬂammatory disorder or underlying malignancy (life
expectancy <2 years); (6) renal dysfunction (estimated
glomerular ﬁltration rate ≤30 mL/min/1.73 m2); (7) poly-
cythaemia; (8) contraindication to ferumoxytol (evidence
of known iron overload, haemochromatosis, known hyper-
sensitivity to ferumoxytol or its components or anaemia
not caused by iron deﬁciency) and (9) contraindication to
iodine-based contrast.
Participant selection and enrolment
Eligible participants will be identiﬁed from the clinical
aneurysm surveillance database and will be approached
by a member of the study team at their ultrasound
appointment. Participants will be supplied with the study
information sheet either in person or by post. Written
informed consent will be obtained from patients willing
to participate in the study. Participants are free to with-
draw from the study at any point or the investigator can
choose to withdraw a participant. If a participant has
consented for the study and then wishes to withdraw,
providing they have not been administered ferumoxytol,
another participant will be recruited in their place.
Study drug
Ferumoxytol
Ferumoxytol (Rienso) is composed of USPIO coated
with polyglucose sorbitol carboxymethylether. It is sup-
plied as an aqueous colloidal product that is formulated
with mannitol and presented in single use vials ready for
intravenous infusion. Each vial contains 510 mg of elem-
ental iron in a volume of 17 mL of mannitol.
The ferumoxytol dose (4 mg/kg) is removed from the
vial and administered intravenously at a rate of up to
1 mL/s. The single dose is given immediately following
the baseline MRI and 24–36 h before the postcontrast
scan. Blood pressure is recorded before and 30 min
after administration to monitor for hypotension. In a
subset of patients (n=20), MRI scanning and USPIO
administration will be repeated at <1 month and 1 year
(up to a total of 3 doses of ferumoxytol in 1 year). Each
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dose of ferumoxytol equates to approximately 7% of
total body iron.
The study drug is manufactured by AMAG
Pharmaceuticals Inc (Lexington, Massachusetts, USA), and
distributed and released by Takeda Italia Farmaceutica SPA
in Europe.
Buscopan
Intravenous Buscopan (hyoscine butylbromide) 20 mg
will be administered before each MRI to reduce artefact
from bowel peristalsis in patients who do not have a
contraindication (allergic reaction, narrow angle glau-
coma, paralytic ileus, myasthaenia gravis, obstructive
prostatic hypertrophy).
Study assessments and data collection
Online supplementary appendix 1 outlines the assess-
ments performed at each study visit. Figure 1 shows
the study ﬂow chart. Patients recruited in Edinburgh
and Glasgow will undergo all study investigations in
their respective centre. For patients recruited from
FVRH, they will have the choice of attending the
study in either Edinburgh or Glasgow. They will con-
tinue to have their surveillance ultrasound scan at
FVRH.
Clinical assessment
Patients will have a full formal and standardised clin-
ical assessment at baseline that will include history,
examination and documentation of cardiovascular
risk factor proﬁle (smoking status, family history,
hypertension, hyperlipidaemia, diabetes mellitus).
Concomitant medications (antihypertensive medica-
tion, etc) will be recorded at baseline and at the end
of the study.
Figure 1 Study flow chart (i.v.,
intravenous).
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Blood sampling
Blood samples (20 mL on each visit) will be collected at
baseline and at 24 months, for routine haematology and
biochemistry including full blood count, urea, creatinine
and electrolytes, liver function tests, total cholesterol
and glucose.
For patients recruited and imaged in the Edinburgh
centre, a further blood sample (9 mL) will be collected
at baseline and at 6, 12, 18 and 24 months. Samples will
be processed (plasma and serum) and stored at −80°C
for later analysis of potential extracellular matrix and
inﬂammatory biomarkers.
Pulse wave analysis and velocity
Pulse wave analysis and velocity will be measured in trip-
licate in fasted patients using applanation tonometry
(SphygmoCor, AtCor Medical, Sydney Australia). This
will facilitate the measurement of central aortic pressure
to assist in the modelling of biomechanical stress within
the aneurysm. This will be measured at baseline and at
6, 12, 18 and 24 months.
Ultrasound of the abdominal aorta
Patients will undergo ultrasound imaging as part of the
standard clinical surveillance programme with measure-
ment of the maximum anteroposterior diameter of the
aneurysm. Ultrasound scans will be performed every 6
±2 months. A 3.5 MHz linear array transducer will be
used to provide standard real time longitudinal B-scan
images of the AAA at the point of maximum diameter.
Maximum anteroposterior AAA diameter and distensibil-
ity (pressure strain elastic modulus and stiffness) will be
assessed. Scans will be undertaken by accredited clinical
vascular scientists with interobserver coefﬁcient of vari-
ation of aortic diameter measurements of 3.5% in our
laboratory.26
CT of the abdominal aorta
Contrast-enhanced images of the abdominal aorta will
be obtained using a 320-multidetector (Edinburgh;
Aquilion ONE; Toshiba) or 64-multidetector CT scanner
(Glasgow; Brilliance 64; Philips), at baseline and 2 years.
These data will be reconstructed into three dimensions
(3D) using volumetric matrices to enable a more com-
prehensive assessment of the aneurysm geometry and
growth than that provided by the ultrasound assessment
of the unidimensional aortic anteroposterior diameter.
In cases where study participants undergo emergency
repair of a ruptured AAA, a CT scan may not be per-
formed. In the event of patients not receiving the CT
scan at baseline it will be performed within 1 month of
the baseline visit.
MRI of the abdominal aorta
MRI will be conducted using a 3 T Siemens Magnetom
Verio scanner (Siemens, Erlangen, Germany) before
and 24–36 h after administration of the USPIO in
Edinburgh or Glasgow. Scanning protocols from the two
centres were validated prior to study initiation. The MRI
safety questionnaire will be applied to identify patients
with a contraindication to scanning. Patients will be
given intravenous Buscopan (hyoscine butylbromide)
prior to imaging to minimise bowel motion artefacts.
Routine clinical coronal and sagittal breath-held
T2-weighted (T2W) multislice HASTE sequences will be
used to identify the position and extent of the aneur-
ysm, following which a respiratory-gated, T2W turbo spin
echo sequence will be used to acquire detailed anatom-
ical data (TR/TE 2500/252 ms; matrix 365×384; ﬁeld of
view 300×400 mm; slice width 5 mm). These data are
acquired with and without Spectral Attenuated Inversion
Recovery fat suppression in order to allow segmentation
of aortic wall. A multiecho, gradient echo T2*W
sequence (TE 4.9, 7.7, 10.5, 13.3 ms; TR 133 ms; ﬂip
angle 15°; matrix 192×256; ﬁeld of view 400×400 mm;
slice width 5 mm) will be used to acquire contiguous
axial images of the entire aneurysm (from the neck of
the aneurysm down to the iliac bifurcation) with slice
positions corresponding to those of the T2W images.
Saturation bands are placed over the anterior abdomen
for the T2*W acquisition in order to minimise
breathing-related artefact.
Clinical management of AAA
The management of AAA in NHS Scotland follows inter-
national27 and national guidelines.28 Elective AAA repair
is considered when the anteroposterior diameter, as
measured by ultrasound scanning, reaches 5.5 cm, the
AAA grows >1 cm in 1 year or the AAA is symptomatic.
Furthermore, the decision for elective AAA repair will
be made by independent clinicians who will be unaware
of the USPIO-enhanced MRI. These clinicians do not
have routine access to the CT scans. However, clinically
important incidental ﬁndings will be communicated to
the clinicians. Study investigators will not be directly
involved in the patient’s care or treatment decisions. In
the case of patients undergoing surgery where repair of
the AAA is not the primary intention (eg, in the case of
repair of a common iliac aneurysm with concomitant
AAA), they will be included in the primary analysis on
an intention-to-treat analysis.
Follow-up for patients in certain circumstances
If a patient undergoes an open or endovascular repair
of their aneurysm, we will record the results of any scans
that are carried out for clinical reasons (such as extra
CT or ultrasound scans). Those undergoing open repair
will have aneurysm wall tissue collected and stored for
the assessment of tissue resident macrophages and
matrix metalloproteinases. These patients will be invited
to return every 6 months for blood tests but not ultra-
sound or pulse wave analysis or velocity.
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Proposed analysis
Image analysis of ultrasound
Cursors will be locked onto echoes representing the
anterior and posterior aortic walls and the movement of
both tracked with each cardiac cycle. The longitudinal
image will be used for analysis as experience with the
technique and data from formal reproducibility studies
indicate that the quality of the data obtained from a lon-
gitudinal section is superior to that obtained from a
transverse view. Images will be captured digitally for later
ofﬂine core laboratory review.
Image analysis of CT
CT of the abdominal aorta will be performed at baseline
and 2 years to assess regional and volumetric growth
rates. These two CT scans will be spatially co-registered
so that areas of expansion and growth can be more
accurately deﬁned, and can permit correlation with
areas of USPIO uptake and ﬁnite element analysis
modelling.
Three-dimensional computer models will be gener-
ated from segmented, contrast-enhanced images, allow-
ing geometric indices to be quantiﬁed. Semiautomatic
segmentation is achievable due to the intensity differ-
ences between the aneurysm, and surrounding tissues
and structures. Intensity thresholding will be used to
identify the lumen. To detect the thrombus and com-
plete the segmentation, we will use a 3D deformable
model approach that utilises the level set algorithm as
well as modelling the thrombus contour as a radial func-
tion starting from the aortic centre line as calculated
from the lumen segmentation.
Image analysis of MRI
A region of interest encompassing the aortic wall and
thrombus but excluding the lumen will be drawn on
each slice of the precontrast T2W image. The precon-
trast T2W scan will be used as the base image to which
subsequent scans will be co-registered using a semi-
automatic rigid 3D voxel registration protocol utilising a
normalised mutual information algorithm. To minimise
the contribution of bowel and abdominal wall motion
in the MRI datasets, a region for registration will include
the aorta, vertebrae and spinal musculature that remain
relatively static during the respiratory cycle, but exclude
the more mobile abdominal wall and bowel.
The four echoes in the multiecho T2*W sequence will
be combined to generate T2* and R2* maps. The T2*
value is the decay constant for the exponential decay of
signal intensity with time and its inverse is the R2* value.
A 3×3 voxel Gaussian ﬁlter will be applied to the individ-
ual echoes to reduce noise, and the coefﬁcient of deter-
mination will be used to exclude data that do not have
an acceptable straight line ﬁt when the log of signal
intensity is plotted against echo time. Images will be
co-registered to allow direct comparison of the precon-
trast and postcontrast T2*W MRI. USPIO uptake will be
presented visually as a colour map of change in T2* or
R2* values between pre-USPIO and post-USPIO scans,
with our previously validated threshold of signiﬁcance
applied (ﬁgure 2).25 The change in T2* or R2* colour
maps from the MRI will be spatially co-registered to the
CT datasets.
Finite element analysis
Using Abaqus/Complete Abaqus Environment, the
vessel wall will be modelled as a constant thickness layer
of 1.5 mm, with a hyperelastic constitutive model.
Thrombus will be modelled as homogeneous and iso-
tropic with Young’s modulus 0.1 MPa. The model will be
inﬂated from diastolic to systolic pressure using a homo-
geneous pressure-modelling regime. Peak wall stress and
other rupture indices will be calculated and compared
against areas of USPIO uptake.
Statistics and data analysis
Sample size calculation
The sample size is determined by the numbers required
to build robust prognostic models for rupture or surgical
Figure 2 Colour map of MRI of an abdominal aortic
aneurysm. Red and yellow pixels indicate areas of increased
T2* value, indicative of ultrasmall superparamagnetic particles
of iron oxide uptake.
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repair, and in particular to measure the additional prog-
nostic value of mural USPIO uptake when added to
such a prognostic model based only on conventional
clinical risk factors. There is a widely accepted ‘rule of
thumb’ that one needs at least 10 and ideally 20
outcome events per covariate to be included in a prog-
nostic model.29 As described in more detail below, we
plan to use the net reclassiﬁcation index (NRI) as the
primary measure of the clinical relevance of the added
prognostic value of mural USPIO uptake.30 31 Based on
two recent papers using the NRI,32 33 and also taking
account of the Harrell ‘rule of thumb’, we estimate that
we need to observe 130 events (ie, the composite of
rupture or surgical repair) to have adequate sensitivity
to answer the primary question. With our estimated
event rate of 41% over the mean duration of follow-up
of 2 years,34 this equates to 317 patients. The estimated
event rate is based on a composite endpoint of rupture
and repair. This is taken from a previous study at our
centre,34 where rupture rates were 13% and elective
intervention rates were in the region of 30% over a
2-year period.
The sample size has been derived so that the study
will allow us to assess the ‘added value’ of USPIO uptake
over and above conventional clinical risk factors in pre-
dicting rupture and/or the need for surgical interven-
tion. As such, conventional type I and II errors are not
relevant. However, the approach we have adopted is
extremely conservative in terms of a conventional power
calculation. For example, if we assume that 40% of the
patients are ‘positive’ for USPIO uptake, and that their
event rate is 55%, compared with an event rate of 30%
in the uptake ‘negative’ patients, then the statistical
power to detect such an effect would be over 99% at the
5% signiﬁcance level (2-sided). In other words, the
study has extremely high power to detect an effect of
the order that would be required if USPIO uptake is to
add usefully to conventional prognostic factors.
There should be very modest losses to follow-up for
the primary analysis, since all study recruits are already
enrolled in a surveillance programme. Moreover, we
shall seek consent at the time of recruitment to ﬂag the
patients so that if any patients are lost to follow-up they
can be traced to identify any hospital admissions or to
identify if they have died. In addition, some patients will
drop out due to technical failure of the scan, such as
claustrophobia or a severe reduction in image quality
preventing analysis. Image quality will be assessed on a
four-point Likert scale (1=excellent; 2=mild reduction in
image quality; 3=moderate reduction in image quality;
and 4=severe reduction in image quality). We have,
therefore, conservatively accounted for a 10% drop out
rate and we will recruit 350 patients to the study.
Statistical analysis
The baseline assessment will include the baseline aneur-
ysm diameter, sex, smoking habit and blood pressure.
Using these covariates, a prognostic model predicting
the time to the composite outcome event of rupture or
surgical repair will be developed using Cox proportional
hazards regression. The added prognostic value of
adding mural USPIO uptake to this model will be
assessed using the increase in the area under the
receiver operator characteristic curve, the Nagelkerke
partial R2 and, primarily, the NRI.32 33 The NRI is a
direct measure of the clinical relevance of adding a cov-
ariate to a prognostic model. It is an overall measure of
how many patients move from a low predicted risk to a
high predicted risk when the covariate is added (and
whether these individuals are indeed high risk), and
how many move from a high predicted risk to a low pre-
dicted risk (and whether these individuals are indeed
low risk). For the primary analysis, the USPIO will be
taken as a binary covariate (as in Richards et al25), but a
sensitivity analysis will explore the potential for including
a quantiﬁcation of the USPIO uptake. Some but not all
of the patients will also have a measure of current aneur-
ysm growth rate at baseline, and a further sensitivity ana-
lysis will explore using growth rate as a further
prognostic factor, using imputation when the estimated
growth rate is not available.
A secondary analysis will follow a similar analytical
strategy to that set out above, but using prognostic
models to predict aneurysm growth rate. This analysis
will be far more complex with the inclusion of serial
measures of aneurysm diameter and with these measure-
ments being censored on rupture or on surgical repair.
Further exploratory analysis will look at the predictive
ability of measures of wall stress and how these interact
with regional USPIO uptake.
The reproducibility of the technique will be assessed
with participants categorised with respect to the presence
or absence of USPIO uptake at 1 month and 1 year, to
deﬁne the proportionate agreement, with 95% CIs.
ETHICS AND DISSEMINATION
Research sponsorship is provided by the Academic and
Clinical Central Ofﬁce for Research and Development
(ACCORD), a partnership between the University of
Edinburgh and NHS Lothian Health Board.
The results of the study will be submitted for publica-
tion in peer-reviewed journals.
Results will also be disseminated through presenta-
tions at national and international conferences.
DISCUSSION
The multicentre MA3RS study will assess the ability of
USPIO-enhanced MRI to augment standard risk
markers for AAA expansion or rupture in 350 patients
attending aneurysm surveillance clinics. This is the ﬁrst
study to assess novel MRI-based imaging approaches to
improve risk prediction in this common and potentially
fatal condition.
Mortality from ruptured AAA is very high, at approxi-
mately 90%. In contrast, the risk of death from open
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surgical or endovascular repair is low, at 1–5%.35 The
aim is therefore to identify AAA prior to rupture and
consider surgery when the risk of rupture exceeds that
of elective repair. Aneurysm screening reduces the risk
of aneurysm-related death by 53–73%, and has been
introduced throughout the UK and in many countries
across the world.1 36 37 Evaluation of rupture risk is cur-
rently based on the maximum anteroposterior diameter
of the aneurysm. Elective aneurysm repair is offered to
patients with an aneurysm diameter of >5.5 cm or if
aneurysm expansion is >1.0 cm/year. However, while the
risk of rupture increases with diameter,8 38 39 the abso-
lute diameter of the aneurysm is not the sole determin-
ant of the risk of rupture,40 and elective repair when the
diameter is <5.5 cm offers no survival beneﬁt over con-
tinued surveillance.41 Furthermore, 1 in 14 screen-
detected aneurysms <5.5 cm in diameter will rupture
within 3 years of detection, and up to one-ﬁfth of rup-
tured AAA are <5.5 cm in diameter, while many patients
present with diameters considerably >5.5 cm without
prior symptoms or rupture.8 41 42 The increase in
patients under long-term surveillance with the introduc-
tion of nationwide screening, coupled with the unpre-
dictability and non-linearity of aneurysm growth,
highlight the need for an improved method of risk pre-
diction in aneurysm disease. This will then enable pre-
ventative surgical or endovascular repair to be targeted
to the high-risk patients.
We have previously demonstrated that the assessment
of USPIO uptake with MRI can be used to detect focal
hotspots of inﬂammation in asymptomatic aneurysms,
and that mural USPIO uptake is associated with more
rapid expansion of aneurysms.25 By assessing these bio-
logical processes and evaluating them with this novel
technique, the MA3RS study aims to develop an
improved method of assessing rupture risk in AAA in a
large prospective clinical study with a long duration of
follow-up.
We will model differing thresholds of risk predictors
that have the potential to inform future interventional
trials. For example, this study could deﬁne USPIO-
enhanced MRI features that predict aneurysm rupture.
This could lead to the design of a major interventional
trial whereby surgical intervention could be targeted at
those aneurysms that are vulnerable or prone to rupture.
This could include surgery in patients with aneurysms
<5.5 cm or mandate conservative management in those
with aneurysms >5.5 cm. A more sophisticated stratiﬁed
approach has the potential to save lives as well as avoid
unnecessary high-risk surgery in those who are unlikely to
come to harm.
Trial status
The study has been approved by the East of Scotland
Research Ethics Committee. Recruitment is underway at
all sites and two-thirds of the study population have
already been recruited. Completion of study enrolment
is anticipated in autumn 2014.
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